Xeris Biopharma Holdings Q2 EPS $(0.18) Misses $0.00 Estimate, Sales $92.100M Beat $90.225M Estimate

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.00 by Infinity percent. This is a 1700 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $92.100 million which beat the analyst consensus estimate of $90.225 million by 2.08 percent. This is a 28.74 percent increase over sales of $71.539 million the same period last year.